Simplified therapeutic intervention to control hypertension and hypercholesterolemia: A cluster randomized controlled trial (STITCH2)

Journal of Hypertension

Volumn 31, Issue 8, 2013, Pages 1702-1713

  Dresser, George K ^a,b   Nelson, Sigrid A E ^a   Mahon, Jeffrey L ^a,b   Zou, Guangyong ^a,d   Vandervoort, Margaret K ^a   Wong, Cindy J ^a   Feagan, Brian G ^a,b,d   Feldman, Ross D ^a,b,c  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c Department of Physiology and Pharmacology ^*  (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

cluster randomization; dyslipidemia management; hypertension management; randomized controlled trial; single pill combination therapy

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE PLUS HYDROCHLOROTHIAZIDE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DRUG DOSE TITRATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 84880570859     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283619d6a     Document Type: Article

References (20)

1. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011; 377:568-577.
2. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan JJ, Paciorek CJ, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011; 377:578-586.
3. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Eagan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47:345-351.
4. Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007; 29:972-984.
5. Nelson SA, Dresser GK, Vandervoort NK, Wong CJ, Feagan BG, Feldman RD. Barriers to blood pressure control: a STITCH substudy. J Clin Hypertens (Greenwich) 2011; 13:73-80.
6. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53:646-653.
7. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010; 122:2078-2088.
8. Khan NA, Hemmelgarn B, Herman RJ, Rabkin SW, McAliser FA, Bell CM, et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 -therapy. Can J Cardiol 2008; 24:465-475.
9. McPherson R, Frolich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006; 22:913-927.
10. Dresser GK, Feldman RD. New trends in hypertension management: of salt, going solo and single pill combos. Curr Opin Cardiol 2010; 25:342-349.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
12. Urbach V, Harvey BJ. Rapid and nongenomic reduction of intracellular [Ca(2+;)] induced by aldosterone in human bronchial epithelium. J Physiol 2001; 537 (Pt 1):267-275.
13. Harvey BJ, D'Agostino RB, Levy D, Bleanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
14. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
15. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007; 30:1638-1646.
16. Lloyd-Jones DM, Wilson PW, Larson MG, Beisar A, Leip EP, D'Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004; 94:20-24.
17. Zarnke KB, Feagan BG, Mahon JL, Feldman RD. A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. Am J Hypertens 1997; 10:58-67.
18. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326:1419.
19. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006; 368:679-686.
20. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010; 122:2078-2088.